IMPACC-MEDVAMC

The objective of this supplement proposal is to understand the causes of airway diseases and thereby improvediagnosis and therapy of these common and debilitating of human ailments. The ImmunophenotypingAssessment in a COVID-19 Cohort (IMPACC) study coordinates a national, multi-institution consortium,collecting detailed clinical data and biologic samples from hospitalized COVID-19 infected individuals, with thegoal of identifying immune signatures/molecular biomarkers associated with clinical disease course, to allowthe prioritization of clinical interventions and decision making. This supplement supports Baylor College ofMedicine's and the Michael E. DeBakey VA Medical Center's (MEDVAMC) participation in IMPACC to facilitatescreening and enrollment of inpatients with COVID-19. The proposed supplement research is within the scopeof parent grant R01 AI135803, Fungal Pathogenesis of Moderate to Severe Asthma. This supplement issubmitted for the purpose of Clinical data and sample collection/processing and the scope will be confined topatients confirmed to have COVID-19. Based on projected trends in COVID-19 disease in MEDVAMC, weestimate that up to 50 COVID-19 patients can be enrolled within 6 months. As enrollees will be followed for upto one year, the budget extends to 18 months. Data to be collected will consist of both primary and secondaryclinical and mechanistic endpoints as well as exploratory clinical and mechanistic endpoints.